MannKind hits 52-week low after Q4 earnings miss
Source: SeekingAlpha
2026-02-26 11:07:02 ET
More on MannKind
- 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
- MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
- MannKind, Liquidia fall as United Therapeutics mulls new treprostinil formulation
- MannKind's Furoscix Autoinjector under FDA review for expanded label
- Seeking Alpha’s Quant Rating on MannKind
Read the full article on Seeking Alpha
For further details see:
MannKind hits 52-week low after Q4 earnings miss
United Therapeutics Corporation
NASDAQ: UTHR
UTHR Trading
-2.94% G/L:
$472.90 Last:
125,751 Volume:
$478.05 Open:
UTHR Latest News
March 03, 2026 07:00:00 am
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 02, 2026 06:30:00 am
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
February 25, 2026 06:30:00 am
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
UTHR Stock Data
$20,237,032,096
38,621,769
0.2%
368
N/A
Biotechnology & Life Sciences
Healthcare
US
Silver Spring
